000			03031cam a2200349 a 4500
003			EG-GiCUC
005			20250223032118.0
008			181119s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2018.Om. R
100	0		_aOmnia Magdy Youssef
245	1	0	_aRole of positron emission tomography/computed tomography in detection of bone marrow involvement in pediatric hodgkin lymphoma / _cOmnia Magdy Youssef ; Supervised Hany Abdelrahman Sayed , Iman Ali Attia , Omnia Kamal Elgebaly
246	1	5	_aدور التصوير المقطعي بالإطار البوزيتروني في اكتشاف مدى تأثر نخاع العظم في سرطان هودجكن الليمفاوي في الأطفال
260			_aCairo : _bOmnia Magdy Youssef , _c2018
300			_a98 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aPurpose: Bone marrow biopsy (BMB) is the standard procedure to detect bone marrowinvolvement in pediatric Hodgkin lymphoma (HL).The role of [18F]{uFB02}uorodeoxyglucose positron emission tomography/computed tomography (FDG-PET) is increasing for the initial staging of HL. We assessed whether routine BMB remains necessary with concomitant FDG-PET/CT. Methods:This retrospective analysis included advanced stage pediatric HL patients over a 6-year period extending from January 2010 till the end of December 2015.BMB results were correlated with FDG-PET/CT findings. Results:The study included 64 advanced stage pediatric HL, their PET/CT scans were positive for Bone marrow(BM) involvement in 35(54.7%) patients and negative in 29(45.3%) patients. BMB results were positive in 14 of 64 patients, only eight of them were identi{uFB01}ed by PET/CT. PET/CT had a sensitivity of 57.1% and a specificity of 46.0%. The positive predictive value was 22.9%, the negative predictive valuewas 79.3%, and the overall diagnostic accuracy was 48.4%. The median follow upwas around 28 months. There was no statistical difference in EFS between (BMB- PET/CT+) and (BMB+ PET/CT-) groups, (72.5% and 50%respectively, P value=0.41). There was no statistical difference in OS between (BMB- PET+) and (BMB+ PET/CT-) groups, (59.3% and 100% respectively, P value= 0.8). EFS didn{u2019}t show significant difference between PET positive (72%)and PET negative patients (76%), (P value = 0.37), but OS was 68.8% for PET positive and 96.6% for PET negative patients (P value= 0.06)
530			_aIssued also as CD
653		4	_aBone marrow
653		4	_aPediatric hodgkin
653		4	_aPositron emission tomography
700	0		_aHany Abdelrahman Sayed , _eSupervisor
700	0		_aIman Ali Attia , _eSupervisor
700	0		_aOmnia Kamal Elgebaly , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c68610 _d68610